Clinical Features and Outcomes of Carcinoma of Unknown Primary Site: A single center experience

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Carcinoma of Unknown Primary Site (CUP)
Presenter Suzy Gohar
Citation Annals of Oncology (2018) 29 (suppl_9): ix170-ix172. 10.1093/annonc/mdy433
Authors S.F. Gohar1, S. Al-Hassanin1, S. Soliman2
  • 1Oncology, Faculty of Medicine - Menoufia University, 32511 - Shebin El Kom/EG
  • 2Public Health And Community Medicine, Faculty of Medicine - Menoufia University, 32511 - Shebin El Kom/EG

Abstract

Background

Carcinoma of unknown primary (CUP) is a heterogeneous entity of malignant epithelial tumors. In general, CUP follows an aggressive biological and clinical behavior. There is generally limited information regarding this issue.

Methods

All patients categorized as having CUP who attended the department of clinical oncology, Menoufia University from January 2013 to December 2015 were included in the study. The patients’ features, investigations and clinical outcomes were collected. Also, time to progression (TTP) and overall survival (OS) were calculated.

Results

The study included 103 patients representing about 2.2% of the total number of patients visited clinical oncology department outpatients’ clinic during the same period. Most of the patients were males, the mean age of the patients was 58 years, pain was the most common presenting symptom, and adenocarcinoma was the most common reported pathological subtype. Only 50.5% of the patients were fit to receive platinum combination chemotherapy. The median TTP was 2 months and the median OS was 3 months. Age, performance status & presenting symptom had statistically significant relation with TTP. While, the baseline performance status, presenting symptoms and pathological subtype had statistically significant relation with OS.

Conclusions

Carcinomas of unknown primary origin are not uncommon tumors in clinical oncology department, Menoufia University with wide varieties of clinical presentations. Baseline performance status, presenting symptoms and pathological subtype had statistically significant relation with OS.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.